Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Zhejiang Conba Pharmaceutical Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 28.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHSE:600572's 3-Year ROIIC % is ranked better than 76.14% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs SHSE:600572: 28.11
Zhejiang Conba Pharmaceutical Co (SHSE:600572) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Zhejiang Conba Pharmaceutical Co 3-Year ROIIC % Related Terms
Zhejiang Conba Pharmaceutical Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co 3-Year ROIIC % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a 3-Year ROIIC % of 28.11 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is near median its historical median of 30.40. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #225 out of 943 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Zhejiang Conba Pharmaceutical Co's 3-Year ROIIC % too high?
Zhejiang Conba Pharmaceutical Co's current 3-Year ROIIC % of 28.11 is near median its 10-year median of 30.40. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. Zhejiang Conba Pharmaceutical Co's value of 28.11 is 689.6% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #225 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #225 out of 943 companies for 3-Year ROIIC %. This places Zhejiang Conba Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.56. Zhejiang Conba Pharmaceutical Co's value of 28.11 is 689.6% above this benchmark. While the company's 10-year median is 30.40 vs. the industry median of 3.56, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current 3-Year ROIIC % of 28.11 is 689.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current 3-Year ROIIC % is 28.11, which is near median its own 10-year median of 30.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.66, compared to a current price of ¥4.30 — trading 24% below its estimated fair value. The current 3-Year ROIIC % is 28.11, which is near median its 10-year median of 30.40 and 689.6% above the Drug Manufacturers industry median of 3.56. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current 3-Year ROIIC % is 28.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.30 is trading 24% below its estimated GF Value™ of ¥5.66.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
3-Year ROIIC %: 28.11 (near median its 10-year median of 30.40)
GF Value™: ¥5.66 vs. price of ¥4.30 (24% below fair value)
Industry Position: 689.6% above the Drug Manufacturers median (#225 of 943)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
75GF Score
Get the complete analysis for SHSE:600572
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
